Cited by 1,736Renin-Angiotensin System StudiesAtherosclerosis and Cardiovascular DiseasesNitric Oxide and Endothelin Effects

Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction

Open access
Guzik, Tomasz J., Hoch, Nyssa E., Brown, Kathryn A., McCann, Louise A., Rahman, Ayaz, Dikalov, Sergey, Goronzy, Jorg, Weyand, Cornelia +1 more·2007·The Journal of Experimental Medicine

Abstract

Hypertension promotes atherosclerosis and is a major source of morbidity and mortality. We show that mice lacking T and B cells (RAG-1−/− mice) have blunted hypertension and do not develop abnormalities of vascular function during angiotensin II infusion or desoxycorticosterone acetate (DOCA)–salt. Adoptive transfer of T, but not B, cells restored these abnormalities. Angiotensin II is known to stimulate reactive oxygen species production via the nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase in several cells, including some immune cells. Accordingly, adoptive transfer of T cells lacking the angiotensin type I receptor or a functional NADPH oxidase resulted in blunted angiotensin II–dependent hypertension and decreased aortic superoxide production. Angiotensin II increased T cell markers of activation and tissue homing in wild-type, but not NADPH oxidase–deficient, mice. Angiotensin II markedly increased T cells in the perivascular adipose tissue (periadventitial fat) and, to a lesser extent the adventitia. These cells expressed high levels of CC chemokine receptor 5 and were commonly double negative (CD3+CD4−CD8−). This infiltration was associated with an increase in intercellular adhesion molecule-1 and RANTES in the aorta. Hypertension also increased T lymphocyte production of tumor necrosis factor (TNF) α, and treatment with the TNFα antagonist etanercept prevented the hypertension and increase in vascular superoxide caused by angiotensin II. These studies identify a previously undefined role for T cells in the genesis of hypertension and support a role of inflammation in the basis of this prevalent disease. T cells might represent a novel therapeutic target for the treatment of high blood pressure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20070657

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The effect is mediated by infiltration of the vascular wall by T lymphocytes and macrophages, leading to production of deleterious cytokines such as IL-17 and TNF-alpha, which contribute to increased vascular resistance driving hypertension and end-organ damage.

    “The effect is mediated by infiltration of the vascular wall by T lymphocytes and macrophages leading to production of deleterious cytokines, such as IL-17 and TNF-α, which, in turn, contribute to the increased vascular resistance driving the hypertension, as well as end-organ damage (61).”
  • Pioneering studies in lymphocyte-deficient mice established that T lymphocytes are required for blood pressure elevations in several hypertension models.

    “Pioneering studies in lymphocyte-deficient mice (Rag1 -/-mice) established that T lymphocytes are required for the BP elevations in several hypertension models (61).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Guzik, T. J., Hoch, N. E., Brown, K. A., McCann, L. A., Rahman, A., Dikalov, S., Goronzy, J., Weyand, C., & Harrison, D. G.
Affiliations
  • Emory University (US)
  • 1Division of Cardiology
  • United States Department of Veterans Affairs (US)
Venue
The Journal of Experimental Medicine
Published
2007-09-17
Volume
204
Issue
10
Pages
2449-2460
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2153626991
Cited by
1,736
References
75
Citations by year
2026: 59 · 2025: 73 · 2024: 78 · 2023: 85 · 2022: 120 · 2021: 117 · 2020: 131 · 2019: 119 · 2018: 99 · 2017: 117 · 2016: 98 · 2015: 107 · 2014: 111 · 2013: 93 · 2012: 82
FWCI
39.09
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institutes of Health (5r01hl059248-04, HL58000)
  • National Heart, Lung, and Blood Institute (HL 58000, HL 59248, R01HL063919, HL 39000 6, HL63919, P01HL058000)
  • National Eye Institute (R01EY011916, EY 11916)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords
T cells, angiotensin II, hypertension, vascular dysfunction, Rag1 knockout mice, adoptive transfer, NADPH oxidase, superoxide production, atherosclerosis, inflammation, T cell homing, CCR5, ICAM-1, RANTES, TNF-α, etanercept, DOCA-salt hypertension
MeSH terms
Angiotensin II, Animals, Cell Movement, Hypertension, Lymphocyte Activation, T-Lymphocytes, Vascular Diseases, Mice, Knockout, NADPH Oxidases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review